BUZZ-BioCryst falls on wider-than-expected quarterly loss

Drugmaker BioCryst Pharmaceuticals' BCRX.O shares fall 11% to $8.20

Co posts Q4 net loss of 13 cents per share, compared with analysts' estimates of a loss of 6 cents per share, according to data compiled by LSEG

Separately in a filing, co discloses it received a notice from India's Annora Pharma in January regarding Annora's submission of an application to the FDA seeking approval to manufacture, use or sell a generic version of BCRX's Orladeyo before the expiration of patents

The letter alleges that the patents, which expire in 2039, are invalid

Orladeyo is used to prevent attacks of hereditary angioedema, a rare genetic disorder that causes severe swelling in the body

BCRX intends to vigorously defend its intellectual property rights protecting Orladeyo, it said

Co posts Q4 revenue of $131.5 million on strong sales for Orladeyo, compared with analysts' estimates of $130.2 million

Expects 2025 total revenue between $560 million and $575 million vs analysts' estimates $545 million

BCRX rose 63% in the last 12 months